MétaCan
Menu
← Retour à la cohorte
Enregistrement W2914582688 · doi:10.1093/cid/ciz115

Reply to Skowronski, De Serres, and Orenstein

2019· letter· en· W2914582688 sur OpenAlexaff
Mark G. Thompson, Michael L. Jackson, Annette K. Regan, Mark A. Katz, Jeffrey C. Kwong, Sarah Ball, Kimberley Simmonds, Nicola P. Klein, Allison L. Naleway

Notice bibliographique

RevueClinical Infectious Diseases · 2019
Typeletter
Langueen
DomaineMedicine
ThématiqueInfluenza Virus Research Studies
Établissements canadiensUniversity of CalgaryInstitute for Clinical Evaluative Sciences
Organismes subventionnairesCenters for Disease Control and Prevention
Mots-clésMedicine

Résumé

récupéré en direct d'OpenAlex

To the Editor—We agree with Skowronski et al [1] that caution is required in conducting and interpreting studies of influenza vaccine effectiveness (IVE) using medical and public health data. Indeed, in our stratified results and discussion, we addressed many of the points the authors raised regarding IVE differences between sites, by illness severity (and thus thresholds for admission), and during peak and nonpeak weeks of influenza circulation [2]. We agree that clinician-ordered testing may bias IVE results if selection of who is tested is associated with both the risk of influenza positivity and the probability of influenza vaccination. Obviously, in the PREVENT cohort, clinicians often tested women with suspected influenza virus infection, and thus influenza positivity was high. Therefore, the risk of bias depends on the association between testing and the probability of vaccination. As we described in our article, published findings regarding this association are mixed. In a simulation study of the possible impact of selection bias on IVE estimates using the test-negative design (TND), Jackson et al found that bias from differential care seeking by patients was only meaningful (ie, reduced a true IVE of 50% by >5%) when vaccination doubled the likelihood of care seeking [3]. If we apply the same model but substitute clinician testing for patient care seeking as the action that selects patients into a study, Jackson et al’s simulation suggests that clinician testing among vaccinated versus unvaccinated pregnant women would have to differ by >2-fold in order to meaningfully bias IVE estimates. We acknowledge that the description of vaccination documentation in our article was limited, and greater detail on these methods is now published [4]. Most prospective IVE networks rely in part or entirely on self-reported vaccination status, which can increase false positive reports and thus reduce specificity of vaccine exposure measurement. In contrast, our study exclusively used vaccination documentation from medical records and registries, which can increase false negative records and thus reduce sensitivity. In a recent simulation study, Jackson et al concluded that low sensitivity presented a lesser risk of bias to IVE estimates using TND than did low specificity; records with only 40% sensitivity to true vaccination status could result in an IVE estimate of 40% when the true IVE is 50% [5]. This is consistent with our interpretation that we likely underestimated true IVE. Finally, we are concerned that a reader might misinterpret Skowronski et al’s observation that we focused on “general laboratory-submissions without standardization of the influenza testing-indication” to mean that we simply sampled all patients with clinical testing. Our study focused on real-time reverse transcription polymerase chain reaction testing among pregnant women hospitalized during weeks of local influenza circulation with a diagnosis associated with influenza in previous studies. Although prospective IVE networks play a vital role in IVE monitoring, further population-based research like PREVENT that builds on our methodological strengths and mitigates limitations is also needed to assess IVE in preventing less frequent and severe outcomes, such as influenza illness that is a primary or secondary cause of hospitalization during pregnancy. Financial support. This study was funded in part by the US Centers for Disease Control and Prevention. Potential conflicts of interest. A. N. reports grants from Pfizer, MedImmune/AstraZeneca, and Merck, outside the submitted work. N. K. reports grants from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Protein Science, Merck & Co, MedImmune, Novartis (now GlaxoSmithKline), and Dynavax, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,006
score de la tête « metaresearch » (Gemma)0,034
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: Sans objet
GenreSignal candidat: Commentaire · Signal consensuel: Commentaire
Score de désaccord entre enseignants0,058
Score d'incertitude au seuil0,033

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0060,034
Méta-épidémiologie (sens strict)0,0010,001
Méta-épidémiologie (sens large)0,0020,001
Bibliométrie0,0010,001
Études des sciences et des technologies0,0040,003
Communication savante0,0040,004
Science ouverte0,0020,002
Intégrité de la recherche0,0580,035
Charge utile insuffisante (le modèle a refusé de juger)0,0070,006

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,099
Tête enseignante GPT0,443
Écart entre enseignants0,345 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSans objet
Domainenon disponible
GenreCommentaire

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations2
Publié2019
Routes d'admission1
Résumé présentnon

Explorer davantage

Même revueClinical Infectious Diseases→Même sujetInfluenza Virus Research Studies→Travaux en français237 207→